drugset / Trial / NCT00002355

A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes

NCT00002355

Completed 60 enrolled Ionis Pharmaceuticals, Inc.
Treatment

Summary

To determine a clinically safe and effective dose of intravitreally injected ISIS 2922 and to compare the safety and efficacy of immediate versus delayed treatment in AIDS patients with previously untreated, peripheral cytomegalovirus ( CMV ) retinitis.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Fomivirsen Unknown 75 ug Intravitreal
Subject Fomivirsen Unknown 150 ug Intravitreal